#GBMDay in the US

Dxcover Ltd joins in recognizing July 17 2024 as #GBMDay in the US Company establishing US operations in Nashville TN

GLASGOW, Scotland and NASHVILLE TN US–(BUSINESS WIRE) – Dxcover Limited, a clinical-stage diagnostics company pioneering its multi-omic spectral analysis (MOSA-Dx) for early detection of solid tumor cancers, joins in recognizing July 17, 2024 as “Glioblastoma Awareness Day” in the US. The 118th Congress recently passed a bi-partisan resolution calling for greater public awareness of glioblastoma, honors those who have been impacted by the disease and supports efforts which improve the long-term prognosis for and quality of life for those impacted by the disease.

While considered a rare cancer, Glioblastoma (GBM) is one of the most complex, deadly and treatment-resistant cancers, accounting for approximately 50% percent of all primary malignant brain tumor diagnoses each year. Once diagnosed, GBM survival rates are often a few months and, despite new therapeutic efforts, have not improved over decades. Unfortunately, therapeutic treatments have not yet significantly improved patient survival nor quality of life.

Chief Executive Officer, Professor Matthew J. Baker said, “Dxcover was founded to enable the earliest detection of cancer. We believe that the combination of Dxcover’s multi-omic spectral analysis and machine learning will lead to the greatest impact on patient recovery, lifespan and quality of life post-diagnosis. We recently launched our EMBRACE study, our UK and pan-Europe 2,200 patient performance evaluation of the Dxcover® Brain Cancer Liquid Biopsy which will enable CE marking and provide a much-needed tool for patients.”

The company has published in both retrospective and prospective clinical studies the Dxcover PANAROMIC™ platform’s detection of brain tumors as small as 0.2 cm3. The company is seeking clinical trial partners to demonstrate the platform’s brain and other solid tumor early detection capabilities in the United States. The entirety of the Resolution can be found here https://www.congress.gov/bill/118th-congress/senate-resolution/735/text.

Dxcover Brain Cancer Liquid Biopsy

About Dxcover Limited.

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple solid tumor cancers, when treatment has a better chance to impact outcomes. The company pioneered Multi-Omic Spectral Analysis for the early detection of cancer by infrared spectroscopy and has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers and adenomas. Dxcover is based in Scotland, United Kingdom and recently incorporated in the US.

For further information go to https://www.dxcover.com/science

The post #GBMDay in the US first appeared on Dxcover.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top